Patel Mayur M
Department of Pharmaceutics, Institute of Pharmacy, Nirma University, SG Highway, Chharodi, Ahmedabad, Gujarat, 382 481, India.
Drug Deliv Transl Res. 2017 Apr;7(2):312-324. doi: 10.1007/s13346-017-0358-7.
Colorectal cancer (CRC) is the third most common cancer globally and the second most common cause of cancer-related deaths. Site-specific delivery of drugs leads to an increase in the availability of drugs at the targeted region. The objective of the present investigation was to develop a dually functional microparticulate colon-targeted drug delivery system of meloxicam for potential application in the prophylaxis of colorectal cancer. Chitosan microspheres were prepared by using emulsification-chemical cross-linking technique. Formulation parameters studied include chitosan concentration, drug to polymer ratio, agitation speed, emulsifier concentration, quantity of cross-linking agent and time for cross-linking. In vitro evaluation of microspheres revealed premature release of drug in the upper part of gastrointestinal tract. Since coating of microspheres is difficult to accomplish (with reproducible results), they were compacted to tablets. Enteric coating of tableted microspheres was achieved using Eudragit® S100. In vitro evaluation and SEM studies depict that the microspheres remain intact during compression process. The developed system was further evaluated for in vivo pharmacokinetic and roentgenography studies. In vivo pharmacokinetic evaluation in rabbits reveal that the onset of drug absorption from the coated tableted microspheres (T = 4.67 ± 0.58 h) was significantly delayed compared to uncoated tableted microspheres. In vivo roentgenographic study revealed that the system remained intact, until it reaches to the colonic region (5 h). Thus, from the results of the study, it can be revealed that the developed system could serve as a potential tool for efficient delivery of drug to the colonic region.
结直肠癌(CRC)是全球第三大常见癌症,也是癌症相关死亡的第二大常见原因。药物的部位特异性递送可提高药物在靶向区域的可用性。本研究的目的是开发一种双功能的美洛昔康结肠靶向药物递送系统,用于结直肠癌预防的潜在应用。采用乳化-化学交联技术制备壳聚糖微球。研究的配方参数包括壳聚糖浓度、药物与聚合物比例、搅拌速度、乳化剂浓度、交联剂用量和交联时间。微球的体外评估显示药物在胃肠道上部过早释放。由于微球的包衣难以完成(且结果可重复),因此将它们压制成片剂。使用Eudragit® S100对压制的微球进行肠溶包衣。体外评估和扫描电子显微镜研究表明,微球在压缩过程中保持完整。对所开发的系统进行了进一步的体内药代动力学和X射线造影研究。家兔体内药代动力学评估显示,与未包衣的压制微球相比,包衣压制微球的药物吸收起始时间(T = 4.67 ± 0.58小时)显著延迟。体内X射线造影研究表明,该系统在到达结肠区域(5小时)之前保持完整。因此,从研究结果可以看出,所开发的系统可作为将药物有效递送至结肠区域的潜在工具。